Mylan N.V. (NASDAQ:MYL) has been upgraded from Mkt Perform to Strong Buy in a statement by Raymond James earlier today.
- Updated: October 10, 2016
Having a price of $35.94, Mylan N.V. (NASDAQ:MYL) traded 8.54% higher on the day. With the last stock price down -11.71% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. MYL has recorded a 50-day average of $41.27 and a two hundred day average of $44.19. Trade Volume was up over the average, with 8,835,533 shares of MYL changing hands over the typical 6,264,440
Raymond James has upgraded Mylan N.V. (NASDAQ:MYL) from Mkt Perform to Strong Buy in a statement released on 10/10/2016.
Recent Performance Chart
Mylan N.V. has PE ratio of 24.69 with a one year low of $35.58 and a one year high of $55.51 and has a market capitalization of $0.
General Company Details For Mylan N.V. (NASDAQ:MYL)
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.